AICAR, an AMPK activator, protects against cisplatin-induced acute kidney injury through the JAK/STAT/SOCS pathway

Biochem Biophys Res Commun. 2019 Feb 12;509(3):680-686. doi: 10.1016/j.bbrc.2018.12.159. Epub 2019 Jan 4.

Abstract

Cisplatin causes acute kidney injury (AKI) through proximal tubular injury. We investigated the protective effect of the adenosine monophosphate protein kinase (AMPK) activator 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) against cisplatin-induced AKI. We investigated whether the AMP-kinase activator AICAR ameliorates cisplatin-induced AKI through the JAK/STAT/SOCS pathway. Male Sprague-Dawley (SD) rats were randomly divided into four groups: control, AICAR, cisplatin, and cisplatin + AICAR. As appropriate to their treatment group, the rats were injected with a single dose of cisplatin (7 mg/kg, i.p.). AICAR was administered to the rats at 100 mg/kg i.p. daily. Blood urea nitrogen (BUN) and serum creatinine were measured. Renal damage was analyzed in sections stained with hematoxylin and eosin (H&E). Renal tissues were also examined by immunohistochemistry and western blot for p-AMPK, Kim-1, cleaved caspase 3, and JAK/STAT/SOCS. For in vitro studies, NRK-52E normal rat kidney cells were treated with cisplatin and/or AICAR. By western blot, we confirmed the expression of p-AMPK and the JAK/STAT/SOCS pathway in NRK-52E cells. AICAR was protective against cisplatin-induced acute tubular injury by up-regulating p-AMPK expression in NRK-52E cells. Protein expression levels of JAK2/STAT1 were markedly ameliorated in NRK-52E cells by AICAR. The protective mechanism of AICAR may be associated with suppression of the JAK2/STAT1 pathway and up-regulation of SOCS1, an inhibitor of the JAK2/STAT1 pathway. The present study demonstrates the protective effects of AICAR against cisplatin-induced AKI and shows a new renoprotective mechanism through the JAK2/STAT1/SOCS1 pathway and apoptosis inhibition. This study suggests that activation of the AMPK activator AICAR might ameliorate cisplatin-induced AKI.

Keywords: 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR); Adenosine monophosphate protein kinase (AMPK); Janus kinase (JAK); Signal transducer and activator of transcription (STAT); Suppressors of cytokine signaling (SOCS).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AMP-Activated Protein Kinases / metabolism
  • Acute Kidney Injury / chemically induced*
  • Acute Kidney Injury / metabolism
  • Acute Kidney Injury / pathology
  • Acute Kidney Injury / prevention & control*
  • Aminoimidazole Carboxamide / analogs & derivatives*
  • Aminoimidazole Carboxamide / therapeutic use
  • Animals
  • Antineoplastic Agents / adverse effects*
  • Cell Line
  • Cisplatin / adverse effects*
  • Enzyme Activators / therapeutic use*
  • Janus Kinases / metabolism
  • Kidney / drug effects
  • Kidney / metabolism
  • Kidney / pathology
  • Male
  • Rats, Sprague-Dawley
  • Ribonucleotides / therapeutic use*
  • STAT Transcription Factors / metabolism
  • Signal Transduction / drug effects*
  • Suppressor of Cytokine Signaling Proteins / metabolism

Substances

  • Antineoplastic Agents
  • Enzyme Activators
  • Ribonucleotides
  • STAT Transcription Factors
  • Suppressor of Cytokine Signaling Proteins
  • Aminoimidazole Carboxamide
  • Janus Kinases
  • AMP-Activated Protein Kinases
  • AICA ribonucleotide
  • Cisplatin